- Reference code :
- wf408
- Published date :
-
20 December 2001
- Expired date :
-
07 May 2029
AstraZeneca and Eli Lilly Company today announced their clinical collaboration to evaluate the benefits of IRESSA™ (ZD1839) in combination with Gemzar® (gemcitabine) for the treatment of various cancers. The clinical collaboration, which will be jointly funded by both companies, will initially assess the combination of the two treatments as part of a Phase II clinical trial programme involving patients with advanced stage non-small cell lung cancer (NSCLC) and bladder cancer. The companies also plan to extend their collaboration to a clinical trial programme which will evaluate the combination of IRESSA and Gemzar in the treatment of various cancers, including breast and ovarian cancers. The clinical collaboration supplements an ongoing Phase III clinical trial, which is investigating the benefits of IRESSA in combination with Gemzar and cisplatin in NSCLC.
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 05:46 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
